SUBSCRIBE: eNewsletter
In this video segment, Dr. Peter Buckley addresses 2 questions:
• What factors do you consider when you offer depot medications to a patient with schizophrenia?
• What can be done to encourage the use of depot medications?
Peter F. Buckley, MD introduces part 1 of our Special Report on schizophrenia.
The personalized medicine approach is predicated upon a greater understanding of the biology of illness and how it plays out—uniquely and specifically—for each individual patient.
The author of this book tells the story of the evolution of psychiatry from a place of skepticism and distain to its more recent emergence as a modern neuroscience.
Has any progress been made in our ability to manage negative symptoms of schizophrenia?
In schizophrenia therapy, the question arises whether a patient with hyper-religiosity as a main symptom can be treated with an antipsychotic (like clozapine) that targets that symptom.
What effect has the new antipsychotic Latuda had in patients with psychosis? Is a mood stabilizer as an adjunctive therapy necessary for schizophrenia or is the use of an antipsychotic alone sufficient?
Weight gain is a known side effect of some medications for schizophrenia. Here: strategies to prevent and manage weight gain.
In schizophrenia therapy, perphenazine can play in combating symptoms and in preventing relapse, though it can be associated with metabolic side effects.
Here: nutritional supplements and over-the counter medications in schizophrenia management.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
